TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tvardi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.97−0.04 (-3.96%)
Close on Oct 19, 2026
- Market cap
- $9.10M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Tvardi Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical compound revenue | – | $84.00K | $165.00K | – | $398.00K | $643.00K | $140.00K | $33.00K | $68.00K | $86.00K | – | – |
| License and milestone fees [Member] | – | – | $910.00K | $15.00M | $21.22M | $134.44M | $19.75M | $13.44M | $530.00K | – | – | – |
| Collaborative revenue | – | $2.09M | $12.94M | $16.57M | $706.00K | – | – | – | $313.00K | – | – | – |
| Royalty revenue | – | – | $415.00K | $72.00K | $0 | $0 | $0 | $0 | – | – | – | – |
| Commercial supply revenue | – | $640.00K | $5.84M | $10.22M | $701.00K | – | – | – | – | – | – | – |
| Other revenue | – | $4.33M | $699.00K | – | – | – | – | – | – | – | – | – |
| Other revenue (non-cash) [Member] | – | $4.33M | $699.00K | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Tvardi Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.